Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics' stock price has been significantly impacted by several events over the past six months. The share price as of March 27, 2026, was $0.68, representing a decline of 67.32% from March 28, 2025. Key events include private placements in December 2025, January 2026 and March 2026, which provided capital but led to dilution for existing shareholders. Aprea Therapeutics reported persistent operating losses, disclosing substantial doubt about its ability to continue as a going concern. Early data from the Phase 1 ACESOT-1051 trial for APR-1051 failed to impress investors, causing the stock to fall. Aprea reported additional positive clinical activity for APR-1051, including confirmed partial responses in patients. Aprea Therapeutics announced management changes in January 2026.

For Aprea Therapeutics, demand seasonality refers to the historical performance patterns of its stock. October has historically been the strongest month for APRE stock, while May has tended to be the weakest month. The overall monthly win rate for the stock is 32.7%, with an average annual return of -59.62%. The seasonal pattern has a consistency score of 73.3 (Very Good).

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel cancer therapeutics within the Biotechnology sector. The company's core focus is on precision oncology, targeting DNA damage response pathways to exploit vulnerabilities in cancer cell mutations while minimizing harm to healthy tissues. Aprea's lead product candidates include APR-1051, an oral WEE1 kinase inhibitor in Phase 1 clinical trials, and ATRN-119 (Mosipasertib), a small-molecule ATR inhibitor in Phase 1/2a clinical trials. The company also has an early-stage program, APRE-DDRi, in the lead optimization stage.

Aprea Therapeutics, Inc. is headquartered in Doylestown, Pennsylvania, and was previously headquartered in Boston, Massachusetts. As a clinical-stage biopharmaceutical company, its primary operations are focused on research and development, with clinical trials conducted in various locations. There is no information available indicating a broad global commercial geographic footprint for product sales at this stage.

Aprea Therapeutics' reputation has been influenced by both challenges and positive developments. Negative impacts include the unimpressive market reception to early clinical data for APR-1051, persistent operating losses, financial uncertainty, and shareholder dilution. Positive impacts include emerging clinical activity for APR-1051, strengthening its global patent portfolio in DNA Damage Response cancer therapeutics, and its mission to develop novel cancer therapies that target cancer cells directly while sparing healthy ones.

Aprea Therapeutics has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 11.42% to 34.19% of the company's stock is held by institutional investors, 6.54% by insiders, and a significant portion (around 81.36%) by public companies and individual investors. Major institutional owners as of December 2025 include AIGH Capital Management LLC, Murchinson Ltd., Sphera Funds Management Ltd., Nantahala Capital Management, LLC, DRW Securities, LLC, Morgan Stanley, Vanguard Group Inc, Citadel Advisors Llc, Jane Street Group, Llc and Geode Capital Management, Llc. Oren Gilad, the CEO, owns the most shares of Aprea Therapeutics Inc.